Direct-Acting Antivirals for Pediatric Chronic Hepatitis C Virus Infection
نویسندگان
چکیده

 Clinical evidence showed that treatment with glecaprevir-pibrentasvir for children and adolescents chronic hepatitis C virus infection was efficacious an overall sustained virologic response 12 weeks after near 100%.
 Glecaprevir-pibrentasvir well-tolerated as there were no serious adverse events or leading to discontinuation. Most mild.
 We did not find any studies evaluated the cost-effectiveness of in pediatric patients.
 peer-reviewed clinical effectiveness sofosbuvir-velpatasvir patients. Unpublished data a conference abstract trial registry suggest sofosbuvir-velpatasvir, but findings should be interpreted cautions.
منابع مشابه
Direct-acting antiviral medications for chronic hepatitis C virus infection.
Treatment of hepatitis C virus has traditionally been difficult because of low rates of treatment success and high rates of treatment discontinuation due to side effects. Current standard therapy consists of pegylated interferon α and ribavirin, both of which have nonspecific and largely unknown mechanisms of action. New therapies are in development that act directly on the hepatitis C virus at...
متن کاملDirect-Acting Antivirals Cure Innate Immunity in Chronic Hepatitis C.
or a number of years, immunologists have strived to Funderstand the mechanisms associated with treatment-induced eradication of hepatitis C virus (HCV). However, interferon (IFN)-a–based therapies did not allow studies examining the role of the virus itself on innate and adaptive immunity to HCV. The study by Serti et al published in this issue of Gastroenterology provides a unique opportunity ...
متن کاملA Viral Dynamic Model for Treatment Regimens with Direct-acting Antivirals for Chronic Hepatitis C Infection
We propose an integrative, mechanistic model that integrates in vitro virology data, pharmacokinetics, and viral response to a combination regimen of a direct-acting antiviral (telaprevir, an HCV NS3-4A protease inhibitor) and peginterferon alfa-2a/ribavirin (PR) in patients with genotype 1 chronic hepatitis C (CHC). This model, which was parameterized with on-treatment data from early phase cl...
متن کاملDirectly acting antivirals against hepatitis C virus.
The approval of directly acting antivirals (DAA) for the treatment of chronic hepatitis C virus (HCV) infection will represent a major breakthrough for the 180 million persons infected worldwide. Paradoxically, hepatitis C is the only human chronic viral disease that can be cured, as all other pathogenic viruses infecting humans either display self-limited courses or establish non-eradicable pe...
متن کاملDirect Acting Antivirals for the Treatment of Chronic Viral Hepatitis
The development and evaluation of antiviral agents through carefully designed clinical trials over the last 25 years have heralded a new dawn in the treatment of patients chronically infected with the hepatitis B and C viruses, but not so for the D virus (HBV, HCV, and HDV). The introduction of direct acting antivirals (DDAs) for the treatment of HBV carriers has permitted the long-term use of ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Canadian journal of health technologies
سال: 2023
ISSN: ['2563-6596']
DOI: https://doi.org/10.51731/cjht.2023.740